We evaluated DSC3 protein expression in bladder cancer and its relationship with the stage of disease as well as with tumor immune infiltrate (TII) to identify the potential of using CADI-05 in the treatment of bladder cancer. This evidence concerns the gene DSC3 and urinary bladder carcinoma.